Tzu‐Ting Huang

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer”.

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Science Translational Medicine(2023)10.1126/scitranslmed.add7872

N/A

0.790DataRank · unranked

25 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert +12 more

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

Oncogene(2020)10.1038/s41388-020-1383-4

N/A

0DataRank · unranked

59 citations

Tzu‐Ting Huang, Junko Murai, Brittany Haynes, Patricia S. Steeg, Yves Pommier +2 more

Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor–Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer

Cancer Research(2020)10.1158/0008-5472.can-20-1439

N/A

0DataRank · unranked

38 citations

Ethan Brill, Jayakumar R. Nair, Xiaohu Zhang, Kelli M. Wilson, Lu Chen +3 more

Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer

Pharmacological Research(2022)10.1016/j.phrs.2022.106162

N/A

0DataRank · unranked

110 citations

Tzu‐Ting Huang, Sachi Horibata, Jung‐Min Lee, Nitasha Gupta

Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer

Oncogene(2022)10.1038/s41388-022-02491-8

N/A

0DataRank · unranked

21 citations

Sandra Burkett, Mayank Tandon, Tomomi M. Yamamoto, Nitasha Gupta, Benjamin G. Bitler +3 more

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

medRxiv(2022)10.1101/2022.12.02.22283037

N/A

0DataRank · unranked

2 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert +12 more

The role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in BRCA wild-type (BRCAwt), platinum-resistant high-grade serous ovarian cancer (PR-HGSOC): Exploratory analysis from a phase II study of CHK1i prexasertib.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5557

N/A

0DataRank · unranked

1 citations

Jayakumar R. Nair, Tzu‐Ting Huang, Min-Jung Lee, Jane B. Trepel, Jungmin Lee +1 more

Data from Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor–Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer

(2023)10.1158/0008-5472.c.6512107

N/A

0DataRank · unranked

0 citations

Ethan Brill, Jayakumar R. Nair, Xiaohu Zhang, Kelli M. Wilson, Lu Chen +3 more

Data from Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor–Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer

(2023)10.1158/0008-5472.c.6512107.v1

N/A

0DataRank · unranked

0 citations

Ethan Brill, Jayakumar R. Nair, Xiaohu Zhang, Kelli M. Wilson, Lu Chen +3 more

579-D Multiplex imaging of ovarian carcinoma reveals spatial cell interaction patterns predictive of immunotherapy responses

DOAJ (DOAJ: Directory of Open Access Journals)(2023)10.1136/jitc-2023-sitc2023.0579-d

N/A

0DataRank · unranked

0 citations

Jung‐Min Lee, Elena Giudice, Edward C. Schrom, Andrea J. Radtke, Nitasha Gupta +4 more

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Nature Communications(2024)10.1038/s41467-024-47215-6

N/A

0DataRank · unranked

42 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome +14 more

AKT1 interacts with DHX9 to Mitigate R Loop–Induced Replication Stress in Ovarian Cancer

Cancer Research(2024)10.1158/0008-5472.can-23-1908

N/A

0DataRank · unranked

28 citations

Chih-Yuan Chiang, Jayakumar R. Nair, Kelli M. Wilson, Ken Cheng, Jung‐Min Lee +1 more

Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological Cancers

Cells(2024)10.3390/cells13121064

N/A

0DataRank · unranked

17 citations

Tzu‐Ting Huang, Jung-Min Lee, Kristen R. Ibanez

Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer

iScience(2024)10.1016/j.isci.2024.111283

N/A

0DataRank · unranked

7 citations

Tzu‐Ting Huang, Anu D. Sunkara, Margaret R. Pruitt, Kristen R. Ibanez, Chih-Yuan Chiang +6 more

Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant BRCA1-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge

Cells(2024)10.3390/cells13221847

N/A

0DataRank · unranked

7 citations

Tzu‐Ting Huang, Jayakumar R. Nair, Kristen R. Ibanez, Jung-Min Lee, Chi-Ting Shih

The KIF18A Inhibitor ATX020 Induces Mitotic Arrest and DNA Damage in Chromosomally Instable High-Grade Serous Ovarian Cancer Cells

Cells(2025)10.3390/cells14231863

N/A

0DataRank · unranked

3 citations

Tzu‐Ting Huang, Maureen M. Lynes, Sanjoy K. Khan, Serena J. Silver, Jungmin Lee +1 more

Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer

Cancer Treatment Reviews(2020)10.1016/j.ctrv.2020.102021

N/A

0DataRank · unranked

169 citations

Erika J. Lampert, Cynthia Coots, Jungmin Lee, Tzu‐Ting Huang

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer

Research Square(2025)10.21203/rs.3.rs-7724642/v1

N/A

0DataRank · unranked

0 citations

Junya Tabata, Tzu‐Ting Huang, Elena Giudice, Kristen R. Ibanez, Jayakumar R. Nair +13 more